Wedbush Reiterates Outperform on Arcus Biosciences, Maintains $43 Price Target

Benzinga Newsdesk www.benzinga.com Negative 73.1%

Neg 73.1% Neu 0% Pos 0%

Wedbush analyst Robert Driscoll reiterates Arcus Biosciences (NYSE:RCUS) with a Outperform and maintains $43 price target.